NeuroPace, Inc. revised earnings guidance for the full year 2023. For the year, the company Increased total revenue guidance to range between $59 million and $61 million, representing growth of 30% to 34% over 2022, as compared to prior guidance of between $52 million and $54 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.46 USD | -6.51% | -8.89% | -37.34% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.34% | 199M | |
+7.31% | 217B | |
+12.99% | 190B | |
+19.71% | 143B | |
+30.60% | 111B | |
+0.65% | 64.59B | |
+15.23% | 52.36B | |
+2.06% | 48.45B | |
-5.49% | 38.03B | |
-0.22% | 35.6B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- NeuroPace, Inc. Revises Earnings Guidance for the Full Year 2023